Resistant social anxiety disorder response to Escitalopram

doi:10.1186/1745-0179-2-35

Clinical Practice and Epidemiology in Mental Health

Volume 2

Viewing options:

Abstract
Full text
PDF (329KB)

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on PubMed Central
Other articles by authors
on Google Scholar

Pallanti S
Quercioli L

on PubMed

Pallanti S
Quercioli L
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Study protocol

Resistant social anxiety disorder response to Escitalopram

Stefano Pallanti¹^,3^,4 and Leonardo Quercioli²^,3

¹Mount Sinai School of Medicine, New York, USA

²Assistant Psychiatrist, Istituto di Neuroscienze, Florence, Italy

³Department of Neurological and Psychiatric Sciences, University of Florence, Italy

⁴Istituto di Neuroscienze, Viale Ugo Bassi 1, 50137 Florence, Italy

Clinical Practice and Epidemiology in Mental Health 2006, 2:35doi:10.1186/1745-0179-2-35


Published:	13 December 2006

Abstract

Background

Social Anxiety Disorder (SAD) is a common disorder and its high prevalence and lifelong chronicity are such that it represents a substantial public health problem. The observation that serotonergic agents appear to be effective for its treatment suggests that patients may have abnormal serotonergic neurotransmission within the central nervous system. We investigated the efficacy of Escitalopram in treatment resistant patients with SAD.

Method

Twenty-nine adult outpatients participated in a 12-week open-label trial of escitalopram. All the subjects had a primary diagnosis of SAD and had failed at least one previous adequate trial of paroxetine. Escitalopram was orally administered starting with a dose of 10 mg/day following a 1-week titration.

Results

The escitalopram treatment was characterized by good tolerability (drop-out rate due to intolerance: 10.3%), and 24 subjects completed the study trial. At the end of the 12-week treatment period, 14 subjects (48.3%) were considered as responders on the basis of the Clinical Global Impression-Improvement (CGI-I) (much or very much improved) scale and the Liebowitz Scale for Social Anxiety (LSAS) (reduction >35% compared to baseline).

We observed a significant mean reduction in the Sheehan Disability Scale Work (p < .05) and Social (p < .05) subscores, but not in the Family subscore.

Conclusion

These data suggest escitalopram has a role in the treatment of resistant SAD, especially in view of the favourable tolerability profile observed in the patients. Controlled studies are required to further investigate these findings and to compare escitalopram with other treatments for this disorder.